Ausgabe 6/2012
Inhalt (40 Artikel)
(+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9
Christian Freise, Wolfram Trowitzsch-Kienast, Martin Ruehl, Ulrike Erben, Daniel Seehofer, Ki Young Kim, Martin Zeitz, Rajan Somasundaram
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients
Maria Cristina Villarroel, Keith W. Pratz, Linping Xu, John J. Wright, B. Douglas Smith, Michelle A. Rudek
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells
Euphemia Leung, Gordon W. Rewcastle, Wayne R. Joseph, Rhonda J. Rosengren, Lesley Larsen, Bruce C. Baguley
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation
Li Wang, Kathy A. Mason, K. Kian Ang, Thomas Buchholz, David Valdecanas, Anjili Mathur, Carolyn Buser-Doepner, Carlo Toniatti, Luka Milas
Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation
Kaouther Kolli-Bouhafs, Abdelaziz Boukhari, Abdurazzag Abusnina, Emilie Velot, Jean-Pierre Gies, Claire Lugnier, Philippe Rondé
Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy
Thierry Marysael, Matthias Bauwens, Yicheng Ni, Guy Bormans, Jef Rozenski, Peter de Witte
Using the neurotransmitter serotonin to target imaging agents to glioblastoma cells
Alexander Sturzu, Sumbla Sheikh, Uwe Klose, Hartmut Echner, Hubert Kalbacher, Martin Deeg, Thomas Nägele, Marius Horger, Ulrike Ernemann, Stefan Heckl
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines
Hyun-Jin Nam, Hwang-Phill Kim, Young-Kwang Yoon, Sang-Hyun Song, Ah-Rum Min, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models
Sharon L. Longo, David J. Padalino, Sandra McGillis, Kirstin Petersen, Hartmut Schirok, Oliver Politz, Gregory W. Canute, Dawn E. Post
Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy
Céline Clémenson, Cyrus Chargari, Laurent Désiré, Anne-Sophie Casagrande, Jean Bourhis, Eric Deutsch
Quinones and halogenated monoterpenes of algal origin show anti-proliferative effects against breast cancer cells in vitro
Jo-Anne de la Mare, Jessica C. Lawson, Maynard T. Chiwakata, Denzil R. Beukes, Adrienne L. Edkins, Gregory L. Blatch
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
David A. Proia, Jim Sang, Suqin He, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Yuan Liu, Shuxia Ye, Dan Zhou, Ronald K. Blackman, Kevin P. Foley, Keizo Koya, Yumiko Wada
Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid inhibits hepatocellular carcinoma in vitro and in vivo via stabilizing IkBα
George G. Chen, Jackie Leung, Nian Ci Liang, Li Li, Kefeng Wu, Ursula P. F. Chan, Billy C. S. Leung, Mingyue Li, Jing Du, Yi Feng Deng, Xianling Gong, Yingnian Lv, Ernest C. W. Chak, Paul B. S. Lai
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer
Chloe E. Atreya, Gregory S. Ducker, Morris E. Feldman, Emily K. Bergsland, Robert S. Warren, Kevan M. Shokat
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas
Angela Ruban, Tamara Berkutzki, Itzik Cooper, Boaz Mohar, Vivian I. Teichberg
Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression
Zarina J. D’Costa, Cheng-Mee Leong, Justin Shields, Charles Matthews, Merilyn H. Hibma
Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling
Alfeu Zanotto-Filho, Elizandra Braganhol, Ana Maria Oliveira Battastini, José Cláudio Fonseca Moreira
Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues
Hua Lv, Fan Wang, M. V. Ramana Reddy, Qingyu Zhou, Xiaoping Zhang, E. Premkumar Reddy, James M. Gallo
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias
Patrick Ziegler, Tuhama Chahoud, Thomas Wilhelm, Nora Pällman, Melanie Braig, Valeska Wiehle, Susanne Ziegler, Marcus Schröder, Chris Meier, Adrian Kolodzik, Matthias Rarey, Jens Panse, Joachim Hauber, Stefan Balabanov, Tim H. Brümmendorf
Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways
Jin Sun Yoon, Young Woong Won, Seo Ju Kim, Suk Joong Oh, Eun Shil Kim, Byoung Kook Kim, Cheon Gyu Cho, Jung Hye Choi, Byeong Bae Park, Min Ho Lee, Young Yiul Lee
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma
Jason Konner, Rachel N. Grisham, Jae Park, Owen A. O’Connor, Gillian Cropp, Robert Johnson, Alison L. Hannah, Martee L. Hensley, Paul Sabbatini, Svetlana Miranov, Samuel Danishefsky, David Hyman, David R. Spriggs, Jakob Dupont, Carol Aghajanian
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
Michael Millward, Timothy Price, Amanda Townsend, Christopher Sweeney, Andrew Spencer, Shawgi Sukumaran, Angie Longenecker, Lonnie Lee, Ana Lay, Girish Sharma, Robert M. Gemmill, Harry A. Drabkin, G. Kenneth Lloyd, Saskia T. C. Neuteboom, David J. McConkey, Michael A. Palladino, Matthew A. Spear
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
C. Massard, R. Salazar, J. P. Armand, M. Majem, E. Deutsch, M. García, A. Oaknin, E. M. Fernández-García, A. Soto, J. C. Soria
First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors
Kazuhiro Araki, Koichi Kitagawa, Hirofumi Mukai, Toru Mukohara, Keiji Kodama, Yuichi Ando, Masaru Narabayashi, Hironobu Minami, Kiyomi Mera, Yasutsuna Sasaki
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
Glen J. Weiss, Manuel Hidalgo, Mitesh J. Borad, Daniel Laheru, Raoul Tibes, Ramesh K. Ramanathan, Lisa Blaydorn, Gayle Jameson, Antonio Jimeno, Jeffrey D. Isaacs, Angela Scaburri, Maria Adele Pacciarini, Francesco Fiorentini, Marina Ciomei, Daniel D. Von Hoff
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study
Warren P. Mason, Mary MacNeil, Petr Kavan, Jacob Easaw, David Macdonald, Brian Thiessen, Shweta Urva, Zarnie Lwin, Lynn McIntosh, Elizabeth Eisenhauer
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, Tateaki Naito, Asuka Tsuya, Yukiko Nakamura, Akira Ono, Nozomu Machida, Kentaro Yamazaki, Junichiro Watanabe, Ana Ruiz-Garcia, Keiji Imai, Emiko Ohki, Nobuyuki Yamamoto
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors
Pamela L. Kunz, Aiwu R. He, A. Dimitrios Colevas, Michael J. Pishvaian, Jimmy J. Hwang, Pamela L. Clemens, Marianne Messina, Remigiusz Kaleta, Fernanda Abrahao, Branimir I. Sikic, John L. Marshall
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
In Gyu Hwang, Joung-Soon Jang, Sung Yong Oh, Suee Lee, Hyuk Chan Kwon, Gyeong Won Lee, Seil Go, Myoung Hee Kang, Young Joo Cha, Jung Hun Kang
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
S. H. Park, M. H. Ryu, B. Y. Ryoo, S. A. Im, H. C. Kwon, S. S. Lee, S. R. Park, B. Y. Kang, Y. K. Kang
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
Thomas Yau, Hilda Wong, Pierre Chan, T. J. Yao, R. Pang, T. T. Cheung, S. T. Fan, Ronnie T. Poon
Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer
Daniel Laheru, Preeti Shah, N. V. Rajeshkumar, Florencia McAllister, Gretchen Taylor, Howard Goldsweig, Dung T. Le, Ross Donehower, Antonio Jimeno, Sheila Linden, Ming Zhao, Dongweon Song, Michelle A. Rudek, Manuel Hidalgo
Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib
Karen E. Mulder, Merrill J. Egorin, Michael B. Sawyer
SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155
Maria Grazia di Iasio, Alessia Norcio, Elisabetta Melloni, Giorgio Zauli
Severe meningo-radiculo-nevritis associated with ipilimumab
Flavie Bompaire, Christine Mateus, Hervé Taillia, Thierry De Greslan, Marion Lahutte, Magali Sallansonnet-Froment, Madani Ouologuem, Jean-Luc Renard, Guy Gorochov, Caroline Robert, Damien Ricard
Aurora kinase inhibitors: Progress towards the clinic
Madhu Kollareddy, Daniella Zheleva, Petr Dzubak, Pathik Subhashchandra Brahmkshatriya, Martin Lepsik, Marian Hajduch
Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?
Andrea Gombos, Otto Metzger-Filho, Lissandra Dal Lago, Ahmad Awada-Hussein
Predictive factors for response to treatment in patients with advanced renal cell carcinoma
Carolina Muriel López, Emilio Esteban, Aurora Astudillo, Pablo Pardo, Jose Pablo Berros, Marta Izquierdo, Guillermo Crespo, Paula J. Fonseca, Miguel Sanmamed, Pablo Martínez-Camblor
Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma
Jason Konner, Rachel N. Grisham, Jae Park, Owen A. O’Connor, Gillian Cropp, Robert Johnson, Alison L. Hannah, Martee L. Hensley, Paul Sabbatini, Svetlana Mironov, Samuel Danishefsky, David Hyman, David R. Spriggs, Jakob Dupont, Carol Aghajanian
Erratum to: Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy
Céline Clémenson, Cyrus Chargari, Laurent Désiré, Anne-Sophie Casagrande, Jean Bourhis, Eric Deutsch